Navigation Links
Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
Date:8/8/2008

for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader in ... new Director of Product Strategy. In this role, Michelle will ... sub-teams to guide in the development of iLab products. Her ... maximum possible benefit to the scientific community by offering the ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Inc., a developer of innovative therapeutics for diseases ... results for the company,s lead product candidate, OTO-104, ... demonstrated that a single intratympanic (IT) injection of ... corticosteroid dexamethasone, provided significant protection against both noise-induced ...
... Feb. 22, 2011 Jennerex, Inc. (San ... appointment of James M. Burke, M.D. to the newly-created ... be responsible for all global clinical research activities related ... has been working with Jennerex in an advisory capacity ...
... KONG, Feb. 22, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation ... first and largest cord blood banking operator in China, today ... was held on February 18, 2011, in Hong Kong. ... Albert Chen and Mark Chen to serve on the Board ...
Cached Biology Technology:Otonomy's OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies 2Otonomy's OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies 3Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research 2China Cord Blood Corporation Announces Results of 2010 Annual General Meeting 2
(Date:7/9/2014)... on the verge of an economy driven by methane, the ... and is undergoing a production boom. It has poised the ... is casting serious doubts over just how climate-friendly it is, ... (C&EN), the weekly news magazine of the American Chemical ... at C&EN, explains that when burned as a fuel to ...
(Date:7/9/2014)... Can thyroid hormone protect neuronal function and increase ... Ailing Fu and her team, School of Pharmaceutical ... in which aged mice were administered with low ... showed that the aged rats exhibited an obvious ... rate from 60% to 93%. The underlying mechanism ...
(Date:7/9/2014)... They are amongst the most numerous inhabitants of the ... . Not visible to the naked eye, when they ... sized patches, they are even visible on satellite images. ... responsible for approximately half of the global photosynthesis output," ... University Jena (Germany). In the process the greenhouse gas ...
Breaking Biology News(10 mins):Short circuit in the food web 2
... of scientists, including University of Colorado School of Medicine ... disease related to an inability to process Vitamin B12. ... "Some people with rare inherited conditions cannot process vitamin ... a geneticist and senior author of a paper about ...
... key role in preserving biological diversity. A new study carried ... (SLU), among others, indicates that if the world,s religious leaders ... positioned to do so. Our study investigates how ... they overlap areas that are important for global biological diversity, ...
... $4.5 million over the next five years for a ... detecting disorders and conditions can and should become a ... one of four projects launched today by the National ... providing genetic sequencing as part of, or instead of, ...
Cached Biology News:Peering into genetic defects, CU scientists discover a new metabolic disease 2Peering into genetic defects, CU scientists discover a new metabolic disease 3Religious leaders can be key to biological diversity 2UCSF receives $4.5M to study value of gene sequencing in newborns 2UCSF receives $4.5M to study value of gene sequencing in newborns 3UCSF receives $4.5M to study value of gene sequencing in newborns 4
... is a new product number, created ... If showing no availability yet, please ... (E6152) or contact customer service for ... diam. 11.25 6.40 in. ...
... Analysis of large numbers of samples may ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z35,347-7) or contact ...
Biology Products: